KRAS and neoplasm: Considering the results that wild-type H and NRAS is required for the mutant KRAS-induced tumor progression,60 degradation of wild-type H and NRAS together with the mutant KRAS provide a benefit for the application of KYA1797K and derivatives as anti-cancer drug candidates.